Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175]

By afschroeder • September 14, 2026

Wu YL, Majem M, John T, Grohé C, Wang J, Goldman JW, Lu S, Shepherd FA, Wang Q, Kato T, Aokage K, Zhong WZ, Laktionov K, Wu MF, Akewanlop C, Vu HV, Lee KH, Huang X, Armenteros-Monterroso E, Rukazenkov Y, Herbst RS. Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA Non-Small Cell Lung Cancer: Exploratory 8-year Overall Survival Landmark Update from the ADAURA Trial [161/175]. J Thorac Oncol. 2026 Sep 13:104179. doi: 10.1016/j.jtho.2026.104179. Epub ahead of print. PMID: 42732874.

Tags: 8-year overall survival, adjuvant therapy, EGFR mutation, Hematology/Oncology, Non-small cell lung cancer, Osimertinib, Publications

Management Patterns and Outcomes for Relapsed or Refractory Hodgkin Lymphoma

Paniker AG, Marshalek JP, Chao E, Yashar D, Tomassetti S. Management Patterns and Outcomes for Relapsed or Refractory Hodgkin Lymphoma. J Hematol. 2026 Aug 31;15(4):188-197.[...]

Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank

Msaouel P, La Rosa S, Abel EJ, Albiges L, Barata PC, Berg SA, Braun DA, Brugarolas J, Campbell MT, Carlo MI, Coleman K, Cost NG,[...]

Lessons from Cohort Studies of Targetable Metabolic Deficiencies in Lung Cancer

Li D, Garon EB. Lessons from Cohort Studies of Targetable Metabolic Deficiencies in Lung Cancer. Clin Cancer Res. 2026 Sep 11. doi: 10.1158/1078-0432.CCR-26-2458. Epub ahead[...]